title: A response to Sher et al, "Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer".
authors.forename: Sean P
authors.initials: SP
authors.lastname: Collins
authors.forename: Simeng
authors.initials: S
authors.lastname: Suy
authors.forename: Leonard N
authors.initials: LN
authors.lastname: Chen
authors.forename: Brian T
authors.initials: BT
authors.lastname: Collins
authors.forename: Anatoly
authors.initials: A
authors.lastname: Dritschilo
mesh_terms: D003362:Cost-Benefit Analysis; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000191:economics* / Q000532:radiotherapy / Q000601:surgery; D016634:Radiosurgery / Q000191:economics*; D050397:Radiotherapy, Intensity-Modulated / Q000191:economics*; D012307:Risk Factors; D016896:Treatment Outcome